A novel DNA vaccine that delivers long lasting immunity by stimulating high avidity CD8 T cells and strong neutralising antibodies

Scancell已经开发出一种快速，低成本和有效的DNA疫苗，它可以刺激强大的免疫反应，杀死癌细胞，并已被证明是安全和有效的治疗皮肤癌患者。这种方法也可用于开发一种安全有效的疫苗，以防止感染病毒，如导致COVID-19的冠状病毒。像其他正在开发的疫苗一样，Scancell将帮助身体产生抗体，阻止COVID-19病毒进入细胞并导致人被感染。我们的疫苗与其他方法的不同之处在于，它还将刺激免疫系统产生特殊的T细胞，这些T细胞可以识别并杀死可能已感染病毒的细胞。这些T细胞也将比抗体在体内停留的时间更长，并在未来感染的情况下存在。Scancell已经生产了两种不同的疫苗：SCOV 1针对病毒的原始武汉毒株，SCOV 2针对包括Delta和Omicron在内的令人担忧的变体。由于英国所有成年人现已接受COVID-19加强注射，Scancell COVID-19疫苗已接种给南非的健康志愿者，那里的疫苗接种率要低得多。Scancell的疫苗使用无针注射装置，易于使用，受患者和志愿者的喜爱，适合在大流行中使用。在健康志愿者中评估SCOV 1和SCOV 2疫苗的安全性和诱导的免疫应答将使我们能够在接种疫苗前的志愿者中进入下一阶段的研究。

Scancell have developed a fast, low cost and effective DNA vaccine which stimulates potent immune responses that can kill cancer cells and has already been shown to be safe and effective in the treatment of patients with skin cancer. This approach can also be used to develop a safe and effective vaccine to prevent infection with viruses such as the coronavirus that causes COVID-19. Like other vaccines being developed, Scancell’s will help the body to make antibodies to stop the COVID-19 virus getting into cells and causing the person to become infected. What makes our vaccine different from other approaches is that it will also stimulate the immune system to make special T cells that can recognise and kill cells that may have been infected with the virus. These T cells will also remain in the body longer than antibodies and be there in case of future infections. Scancell has made two different vaccines: SCOV1 targets the original Wuhan strain of the virus and SCOV2 targets variant of concern, including Delta and Omicron. As all adults in the UK have now been offered a COVID-19 booster injection, the Scancell COVID-19 vaccines have been administered to healthy volunteers in South Africa where vaccination rates are much lower. Scancell’s vaccines are being given using a needle-free injection device which is easy to use, liked by patients and volunteers, and suitable for use in a pandemic. Evaluation of the safety profile and immune responses induced by the SCOV1 and SCOV2 vaccines in healthy volunteers will allow us to move into the next phase of the study in pre-vaccinated volunteers.